Beryl Drugs Ltd
Beryl Drugs Ltd (BERLDRG) last reported results for the quarter ended Jun 2026, with sales of ₹7.57 crore and net profit of ₹0.22 crore. The stock last traded at ₹26, a market capitalisation of ₹13.2 crore, on a P/E of 21.2. Over the past 52 weeks the stock has ranged between ₹15.9 and ₹27.6. Figures are as of 6 Oct 2026 and are not real time.
Beryl Drugs Ltd share price and key metrics
- Current price
- ₹26
- Market cap
- ₹13.2 cr
- Stock P/E
- 21.2
- Book value
- ₹19.5
- ROE
- 4.34%
- ROCE
- 7.25%
- Dividend yield
- 0.00%
- 52w high / low
- 27.6/15.9
Metrics as of 6 Oct 2026. Not real time.
Track Beryl Drugs Ltd
Cruxal reads every Beryl Drugs Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Beryl Drugs Ltd growth and returns
- 10 Years
- 4%
- 5 Years
- 6%
- 3 Years
- -11%
- TTM
- 5%
- 10 Years
- 9%
- 5 Years
- 44%
- 3 Years
- -18%
- TTM
- 170%
- 10 Years
- 4%
- 5 Years
- 7%
- 3 Years
- 6%
- 1 Year
- 4%
- 10 Years
- 3%
- 5 Years
- 4%
- 3 Years
- 6%
- Last Year
- 4%
Beryl Drugs Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹7.57 cr, up 56.7% from ₹4.83 cr a year earlier. Net profit was ₹0.22 cr, up 1000.0% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 5.64 | 5.4 | 5.22 | 4.83 | 5.16 | 3.85 | 5.47 | 7.57 |
| Expenses | 5.08 | 4.81 | 4.72 | 4.28 | 4.43 | 4.05 | 4.13 | 6.92 |
| Operating profit | 0.56 | 0.59 | 0.5 | 0.55 | 0.73 | -0.2 | 1.34 | 0.65 |
| OPM % | 9.93% | 10.93% | 9.58% | 11.39% | 14.15% | -5.19% | 24.50% | 8.59% |
| Other income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest | 0.12 | 0.12 | 0.08 | 0.1 | 0.08 | 0.09 | 0.07 | 0.06 |
| Depreciation | 0.33 | 0.31 | 0.32 | 0.38 | 0.39 | 0.32 | 0.4 | 0.32 |
| Profit before tax | 0.11 | 0.16 | 0.1 | 0.07 | 0.26 | -0.61 | 0.87 | 0.27 |
| Tax % | 90.91% | 62.50% | -50.00% | 71.43% | 96.15% | -72.13% | 34.48% | 18.52% |
| Net profit | 0.01 | 0.05 | 0.15 | 0.02 | 0.01 | -0.17 | 0.56 | 0.22 |
| EPS (₹) | 0.02 | 0.10 | 0.30 | 0.04 | 0.02 | -0.34 | 1.10 | 0.43 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Beryl Drugs Ltd annual results
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 10.9 | 15.08 | 12.81 | 12.78 | 14.03 | 14.48 | 26.84 | 26.73 | 21.15 | 18.81 | 22.05 |
| Operating profit | -0.06 | 1.04 | 1.03 | 0.91 | 1.45 | 0.44 | 2 | 2.28 | 1.24 | 1.94 | 2.52 |
| OPM % | -0.55% | 6.90% | 8.04% | 7.12% | 10.33% | 3.04% | 7.45% | 8.53% | 5.86% | 10.31% | 11.43% |
| Net profit | -0.45 | 0.99 | 0.59 | 0.05 | 0.24 | -0.66 | 0.77 | 0.77 | 0.57 | 0.42 | 0.62 |
| EPS (₹) | -0.89 | 1.95 | 1.16 | 0.10 | 0.47 | -1.30 | 1.52 | 1.52 | 1.12 | 0.83 | 1.21 |
TTM is the trailing twelve months to the most recent quarter.
Beryl Drugs Ltd balance sheet
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Equity capital | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 | 5.09 |
| Reserves | 0.79 | 1.57 | 2.43 | 2.53 | 2.84 | 2.20 | 2.97 | 3.83 | 4.39 | 4.79 |
| Borrowings | 1.72 | 1.48 | 3.25 | 5.23 | 5.12 | 5.29 | 4.54 | 5.09 | 4.12 | 2.44 |
| Other liabilities | 2.85 | 2.69 | 3.80 | 4.07 | 5.60 | 5.25 | 4.92 | 3.48 | 2.38 | 2.65 |
| Total liabilities | 10.45 | 10.83 | 14.57 | 16.92 | 18.65 | 17.83 | 17.52 | 17.49 | 15.98 | 14.97 |
| Fixed assets | 2.25 | 2.22 | 1.96 | 8.60 | 7.52 | 6.04 | 6.03 | 6.17 | 6.24 | 7.04 |
| CWIP | 0.00 | 0.08 | 6.24 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.49 | 0.22 | 0.48 | 0.56 | 0.12 | 0.16 | 0.15 | 0.00 | 0.00 | 0.00 |
| Other assets | 7.71 | 8.31 | 5.89 | 7.76 | 11.01 | 11.63 | 11.34 | 11.32 | 9.74 | 7.93 |
| Total assets | 10.45 | 10.83 | 14.57 | 16.92 | 18.65 | 17.83 | 17.52 | 17.49 | 15.98 | 14.97 |
As reported by the company. Total assets equal total liabilities by construction.
Beryl Drugs Ltd cash flow
| ₹ crore | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | 0.37 | -0.10 | 3.35 | 0.18 | 0.34 | -0.29 | 2.48 | 0.82 | 3.29 | 3.65 |
| Cash from investing | 0.32 | -0.03 | -5.01 | -1.55 | 0.26 | 0.54 | -1.30 | -1.08 | -1.05 | -2.16 |
| Cash from financing | -0.19 | -0.36 | 1.62 | 1.67 | -0.54 | -0.43 | -1.17 | 0.10 | -1.56 | -2.03 |
| Net cash flow | 0.50 | -0.49 | -0.04 | 0.30 | 0.06 | -0.18 | 0.01 | -0.16 | 0.69 | -0.54 |
| Free cash flow | 0.19 | -0.01 | -2.87 | -1.70 | 0.10 | 0.10 | 1.73 | -0.51 | 1.10 | -0.17 |
| CFO / operating profit | -833% | 1% | 350% | 36% | 25% | -43% | 127% | 45% | 280% | 196% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Beryl Drugs Ltd operating ratios
| Per year | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | -2.26% | 11.94% | 9.94% | 4.06% | 2.86% | -3.82% | 11.60% | 11.05% | 10.07% | 7.25% |
| Debtor days | 102.47 | 116.91 | 98.02 | 98.53 | 118.11 | 112.17 | 93.83 | 103.51 | 94.23 | 40.56 |
| Inventory days | 151.29 | 53.10 | 39.74 | 486.67 | 1,135.00 | — | 245.67 | — | — | — |
| Days payable | 65.24 | 57.03 | 93.60 | 755.17 | 1,110.00 | — | 758.08 | — | — | — |
| Cash conversion cycle | 188.52 | 112.97 | 44.16 | -169.97 | 143.11 | 112.17 | -418.57 | 103.51 | 94.23 | 40.56 |
| Working capital days | 67.31 | 71.89 | -6.55 | 13.99 | 38.76 | 47.14 | 46.51 | 57.90 | 68.00 | 40.36 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Beryl Drugs Ltd shareholding pattern
Promoters held 27.82% at Jun 2026, up from 26.38% at Jun 2025.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 26.38% | 26.38% | 26.38% | 26.38% | 26.38% | 26.38% | 27.48% | 27.82% |
| Public | 73.62% | 73.62% | 73.61% | 73.61% | 73.62% | 73.62% | 72.53% | 72.19% |
| No. of shareholders | 7,364 | 7,429 | 7,431 | 7,415 | 7,446 | 7,409 | 7,349 | 7,309 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Beryl Drugs Ltd corporate filings
- CERTIFICATE UNDER REGULATION 74(5) OF SEBI (DP) REGULATIONS, 2018 FOR THE QUARTER ENDED 30.09.2026Company Updatelow impact
- Beryl Drugs Ltd files non-applicability certificate under Regulation 57(5) for quarter ended 30.09.2026Otherslow impact
Cruxal's analysis: The company has submitted a compliance certificate indicating non-applicability for the…
Read the full analysis - CLOSURE OF TRADING WINDOWInsider Trading / SASTlow impact
- Beryl Drugs Limited Declares Results with Notable Revenue and Profit Fluctuations; AGM Voting Results Indicate Strong Shareholder Support for Key ResolutionsAGM/EGMmedium impact
Cruxal's analysis: Beryl Drugs Limited reported quarterly revenues ranging from approximately 3.21 crore to…
Read the full analysis - PROCEEDINGS OF 33RD ANNUAL GENERAL MEETINGAGM/EGMmedium impact
- Beryl Drugs Ltd approves increase in material related party transaction limits with Aminova Infusions Pvt. Ltd.Company Updatelow impact
Cruxal's analysis: Beryl Drugs Ltd has formally approved an increase in the limit for material related party…
Read the full analysis - Beryl Drugs Limited concludes 33rd Annual General Meeting with approval of financial statements and related party transaction limitsAGM/EGMlow impact
Cruxal's analysis: Beryl Drugs Limited has successfully concluded its 33rd Annual General Meeting held on 29…
Read the full analysis - Beryl Drugs Ltd announces newspaper publication of 33rd Annual General Meeting noticeCompany Updatelow impact
Cruxal's analysis: Beryl Drugs Ltd has fulfilled regulatory requirements under Regulation 30 of the SEBI…
Read the full analysis - Beryl Drugs Ltd releases Annual Report for the financial year 2025-2026Otherslow impact
Cruxal's analysis: Beryl Drugs Ltd has filed its Annual Report for the fiscal year 2025-2026 in compliance…
Read the full analysis - Beryl Drugs Limited Announces 33rd AGM and Proposes Increase in Related Party Transaction Limit with Aminova InfusionsAGM/EGMmedium impact
Cruxal's analysis: Beryl Drugs Limited has issued a notice for its 33rd Annual General Meeting scheduled for…
Read the full analysis - Beryl Drugs Ltd announces e-voting dates for 33rd Annual General MeetingCompany Updatelow impact
Cruxal's analysis: Beryl Drugs Ltd has scheduled the e-voting process for its 33rd Annual General Meeting…
Read the full analysis - Beryl Drugs Ltd announces record date for 33rd Annual General MeetingCorp. Actionlow impact
Cruxal's analysis: Beryl Drugs Ltd has notified the exchange regarding the record date for its 33rd Annual…
Read the full analysis - Beryl Drugs Ltd announces annual book closure for AGMCorp. Actionlow impact
Cruxal's analysis: Beryl Drugs Ltd has issued an intimation regarding the annual book closure for its…
Read the full analysis - Beryl Drugs Limited Announces Board Approval for 33rd AGM and Increase in Related Party Transaction LimitsBoard Meetinglow impact
Cruxal's analysis: Beryl Drugs Limited has announced the outcome of its board meeting held on September 2…
Read the full analysis - Beryl Drugs Limited schedules Board Meeting for 33rd AGM and related party transaction limit reviewBoard Meetinglow impact
Cruxal's analysis: Beryl Drugs Limited has announced a Board Meeting scheduled for September 2, 2026…
Read the full analysis - Beryl Drugs Limited: Promoter Sudhir Sethi increases stake by 0.10% via open market purchaseInsider Trading / SASTlow impact
Cruxal's analysis: Beryl Drugs Limited has disclosed that its promoter, Mr. Sudhir Sethi, acquired 4,809…
Read the full analysis - Beryl Drugs Limited: Promoter Sudhir Sethi increases stake by 0.06% via open market purchaseInsider Trading / SASTlow impact
Cruxal's analysis: Beryl Drugs Limited has disclosed that its main promoter, Mr. Sudhir Sethi, acquired…
Read the full analysis - Beryl Drugs Limited Reports Strong Q1 FY2027 Financial Results with Significant YoY Profit GrowthCompany Updatehigh impact
Cruxal's analysis: Beryl Drugs Limited has reported unaudited financial results for the quarter ended 30…
Read the full analysis - Beryl Drugs Limited Reports Q1 FY2027 Financial Results with Significant YoY Revenue GrowthResulthigh impact
Cruxal's analysis: Beryl Drugs Limited reported a strong performance for the quarter ended 30 June 2026…
Read the full analysis - Beryl Drugs Limited Announces Outcome of Board Meeting Regarding June 2026 Quarterly ResultsBoard Meetinglow impact
Cruxal's analysis: Beryl Drugs Limited has formally announced the conclusion of its board meeting held on…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.